Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCW BiologicsHCWB +2.83%37 Net Cash per Share is $-11.50 as of Jun. 2026. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $36.45 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 757 Biotechnology companies, HCW Biologics ranks worse than 132100.26% on this metric.
The historical rank and industry rank for HCW Biologics's Net Cash per Share or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Cash Ratio of HCW Biologics was 12.00. The lowest was 2.41. And the median was 2.97.
HCWB's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.17 * Ranked among companies with meaningful Price-to-Net-Cash only.
HCW Biologics (NAS:HCWB) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
HCW Biologics Net Cash per Share Related Terms
HCW Biologics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs GOVX, GLMD, SXTP: Net Cash per Share Comparison
For the Biotechnology subindustry, HCW Biologics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
HCW Biologics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Net Cash per Share of $-11.50 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on HCW Biologics and its competitors. Over the past decade, HCW Biologics' Net Cash per Share has ranged from 2.41 to 12.00. According to the industry distribution chart, HCW Biologics ranks #999999 out of 757 companies in the Biotechnology industry.
Is HCW Biologics' Net Cash per Share too high?
HCW Biologics' current Net Cash per Share is $-11.50. Over the past 10 years, this metric has ranged from a low of 2.41 to a high of 12.00. Based on the distribution chart, HCW Biologics ranks #999999 out of 757 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Net Cash per Share compare to GOVX and GLMD?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #999999 out of 757 companies for Net Cash per Share. This places HCW Biologics in the lower half of its industry. The industry median Net Cash per Share is 5.17. Historically, HCW Biologics' own Net Cash per Share has ranged from 2.41 to 12.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.17, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Net Cash per Share is $-11.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $36.45, compared to a current price of $2.18 — trading 94% below its estimated fair value. The current Net Cash per Share is $-11.50. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Net Cash per Share is $-11.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $2.18 is trading 94% below its estimated GF Value™ of $36.45.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Net Cash per Share: $-11.50
GF Value™: $36.45 vs. price of $2.18 (94% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score
Get the complete analysis for HCWB
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
